Immuron Limited · ASX:IMC
Immuron — Investor Presentation (January 2014)
28 slides from Immuron's investor presentation, Jan 22, 2014
Slide 1: Investor Presentation January 2014
For personal use only Investor Presentation January 2014 Chief Executive Officer - Amos Meltzer ORAL IMMUNOTHERAPY USING BOVINE ANTIBODIES 1
Slide 2: Forward-looking Statement
Forward-looking Statement For personal use only Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guida
Slide 3: Investment highlight
Investment highlight For personal use only • Safe and proven technology platform • Rich product pipeline • Travelan® approved and already in market generating sales – Revenues growing and set to accelerate. • 2nd product: Fatty liver / NASH – an expected off-label use $3.2B market by 2016 in the US
Slide 4: Company Overview
For personal use only Section 1 Company Overview 4
Slide 5: Corporate Structure
Corporate Structure For personal use only New Cornerstone investors ASX Code IMC Shares on Issue 1,053,679,310 Current Share price 1.0 c Top 20 holders 55.4% Rank Name Units (m) % of Units 1. GRANDLODGE PTY LTD 101.6 9.8 2. MR PETER ANASTASIOU + MRS KRISTINE PATRICIA ANASTASIOU <ANASTASIOU SUPER FUN
Slide 6: Board and Management
Corporate Structure Board and Management For personal use only • Chairman - Dr Roger Aston Founding CEO of Mayne Pharma Group; experience with FDA and EU product registration, clinical trials, global licensing agreements & fundraising • Non-executive Director – Daniel Pollock Internationally experie
Slide 7: The Platform: Points of Difference
The Platform Points of Difference For personal use only Product Other products Natural product Synthetic product Powerful systemic immuno-modulatory Immune modulation can be achieved effect Does not suppress immunity Can suppress immunity Proven: no side effects or toxicity Some side effects or toxi
Slide 8: The Pipeline
The Pipeline For personal use only Indication Research Pre-Clinical Phase I Phase II Phase III Market Traveller’s Diarrhea NASH (IMM-124E) ASH (IMM-124E) Clostridium difficile infection Other Projects: Related to Liver Related to IMM-124E And other indications 8
Slide 9: Travelan
For personal use only Section 2 TRAVELAN 9
Slide 10: Travelan
TRAVELAN The last 3 years For personal use only • Unique: Prevents travellers’ diarrhoea All other products are treatments and typically start to provide benefits only 48-72 hours after the onset of an attack • All Natural • Accessible: over-the-counter. • It works: Clinically proven, >90% efficacy
Slide 11: Travelan In Market, the last 3 years
For personal use only 0 1,000 2,000 3,000 4,000 5,000 6,000 Jan-10 Feb-10 Mar-10 Apr-10 TRAVELAN May-10 Jun-10 Jul-10 Aug-10 Sep-10 License with Takeda Oct-10 Nov-10 In Market, the last 3 years Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-11 Jul-11 Aug-11 TRAVELAN Sep-11 Oct-11 Nov-11 Dec-11 Jan-12
Slide 12: Travelan Australia
TRAVELAN Australia For personal use only Previous arrangement: R e t a I l e r s Wholesalers Current arrangement (from July 2013): R e t a I l e r s Wholesalers Immuron is commanding substantially higher margin 12
Slide 13: Travelan Going Forward
TRAVELAN Going Forward For personal use only Approved In Discussion In Discussion Various stages of ` regulatory ` process ` Licensed In Discussion ` In Revenue ` Proceeding through 13 regulatory process
Slide 14: IMM-124E for NASH
For personal use only Section 3 IMM-124E for NASH 14
Slide 15: NASH: How big is the opportunity?
NASH How big is the opportunity? For personal use only Intercept Pharmaceuticals (NASDAQ: ICPT) $1.5B before more than quadrupling overnight What this mean for Immuron: on NASH trial results Scientifically Market cap: $8.5B • NASH is addressable Commercially January 9, 2014: • There is a huge, unmet
Slide 16: NASH: The Epidemic
NASH The Epidemic For personal use only Fatty liver: one of most common liver diseases in the industrialized world NASH – An Epidemic of Non-Alcoholic Steatohepatitis (NASH): the most severe form of liver NCID : injury in the spectrum of >25M AMERICANS WILL HAVE NASH non-alcoholic fatty liver BY 202
Slide 17: IMM-124E for NASH: Ready to go Phase 2B trial
IMM-124E for NASH Ready to go: Phase 2B trial For personal use only Based on existing technology: - Mature manufacturing process - High Safety profile IND cleared by the FDA: Immuron set to commence clinical trials Preparations under way Investigators identified IMM-124E has been independently valid
Slide 18: IMM-124E for NASH: Mechanism of Action
IMM-124E for NASH Mechanism of Action For personal use only Oral Immunotherapy: An approach to treating autoimmune, infectious and inflammatory disease through the oral delivery of antibodies Scientific support for Immuron’s approach continues to grow Immuron has the right product at the right time
Slide 19: Clinically Proven
Clinically Proven 120.0 120.0 INTRODUCTION For personal use only 100.0 100.0 9.0 Day Day GGT levels (u/L) AP levels (u/L) 80.0 80.0 8.0 1 30 • Metabolic syndrome is a chronic inflammatory 49.01% 5.66% 60.0 60.0 7.0 10 5 g a te d c e lls (% ) disorder associated with insulin resistance and 6.0 40.0 C
Slide 20: R&D Pipeline
For personal use only Section 4 R&D PIPE LINE 20
Slide 21: IMM-529 for Clostridium difficile
IMM-529 for Clostridium difficile For personal use only • Clostridium difficile (C.diff): a bacteria normally found in people’s intestines. • Certain circumstances C.diff can multiply and its toxin causes illness such as diarrhoea & severe inflammation of the bowel. C.diff infection accounts for: •
Slide 22: IMM-529 for Clostridium Difficile: Very encouraging results
IMM-529 for Clostridium Difficile Very encouraging results to date For personal use only • IMM-529 under collaboration with Monash University • All data owned by Immuron • IMM-529 demonstrated positive pre-clinical results: • Encouraging preventative data • Treatment effect currently being investiga
Slide 23: Looking Ahead
For personal use only Section 5 LOOKING AHEAD 23
Slide 24: 2013: The Achievements
2013: THE ACHIEVEMENTS For personal use only April rights issue: high net worth investors who provide a lot of New Shareholders support Direct-to-wholesale model in Australia, increase revenues Regulatory approval in Canada Travelan: continue commercialization Regulatory progress in licensed territo
Slide 25: Looking Ahead: What we are seeking to achieve
LOOKING AHEAD What we are seeking to achieve For personal use only Financial Strength Improve balance sheet More licenses Travelan: continue commercialization More revenue Commence Phase IIb Clinical trial Fatty Liver / NASH Partner Progress to the clinic with another product Progress R&D A number o
Slide 26: Summary
For personal use only Section 6 SUMMARY 26
Slide 27: The Opportunity
THE OPPORTUNITY For personal use only Immuron presents a unique opportunity: The present: The near term future: The rich pipe line: Current market cap of Addressing large unmet medical Immuron’s technology ~$10M can be justified need in red hot area: NASH / fatty supports a rich pipeline based on th
Slide 28: Thank you / Contact
THE OPPORTUNITY For personal use only Thank you Contact Amos Meltzer – Chief Executive Officer Ph: 0437 587 680 28